Drugs / Briquilimab
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05600907 | Jan 2023 → Nov 2036 expected | chronic granulomatous disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT06592768 | Nov 2024 → Aug 2025 | allergic asthma | Jasper Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05903274 | Jun 2023 → Oct 2024 | myelodysplastic syndrome | Jasper Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04429191 | Jul 2020 → Oct 2023 | acute myeloid leukemia, myelodysplastic syndrome | Jasper Therapeutics, Inc. | Unknown | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06353971 | Mar 2024 → Jul 2025 | chronic inducible urticaria | Jasper Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT06162728 | Nov 2023 → Oct 2026 expected | chronic idiopathic urticaria | Jasper Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05357482 | May 2022 → Jan 2026 overdue | beta thalassemia, sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04784052 | Dec 2021 → Dec 2027 expected | Fanconi anemia | Porteus, Matthew, MD | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02963064 | Mar 2017 → Jul 2025 | severe combined immunodeficiency | Jasper Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06736262 | Nov 2024 → Aug 2026 overdue | chronic urticaria | Jasper Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05907746 | Nov 2023 → Oct 2025 overdue | GATA2 deficiency with susceptibility to MDS/AML | National Institutes of Health Clinical Center (CC) | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06145282 Background | Dec 2023 → Oct 2025 overdue | sickle cell disease | National Heart, Lung, and Blood Institute (NHLBI) | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Briquilimab | “Briquilimab is a monoclonal antibody inhibiting stem cell factor (SCF) binding to CD117 (c-Kit).” PMID 41785374 ↗ May 2026 |
| Known as | AMG191 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095110 ↗ |
| Known as | JSP191 | “a new antibody drug (briquilimab, JSP191) improves the success of a blood stem cell transplant” NCT05357482 ↗ |
| Known as | JSP191 (Briquilimab) | “JSP191 (Briquilimab)” NCT05903274 ↗ |
| Action | Inhibit | “The binding of JSP191 to CD117 blocks CD117 from binding to Stem Cell Factor on blood forming stem cells.” NCT02963064 ↗1“Stem cell growth factor receptor inhibitor” CHEMBL5095110 ↗ |
| Modality | Monoclonal antibody | “The biological conditioning regimen, JSP191, is an antibody that binds to CD117.” NCT02963064 ↗ |
| Route | Intravenous | “Procedure: single intravenous infusion of JSP191 antibody” NCT02963064 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL5095110 ↗ |